← All diseases Cancer

Chronic lymphocytic leukemia

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchStrongest evidence only (63)Meta-analysis (7)Treatment guideline (3)Phase 3 study (32)Systematic review (13)Randomized trial (8)Clinical trial (588)Review article (208)Early study (phase 1 or 2) (38)Case report (197)Laboratory or animal study (14)Commentary or editorial (62)Retracted publication (2) Studies currently seeking participants only (43)

Filter

Publications (1168)

• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Resistance pathways and next-generation treatments in chronic lymphocytic leukaemia. (2026/06/02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study. (2026/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy. (2026/05/14) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Refractory chronic lymphocytic leukemia-associated pruritus successfully treated with nemolizumab. (2026/05/05) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan. (2026/05/01) ♡
• A Novel Boundary-Aware Transformer Based Fire Hawk Algorithm for Leukemia Classification using Blood Smear Images. (2026/05/01) ♡
• Identification of Potential Biomarkers for Intervention of AMG-176 in the Chronic Lymphocytic Leukemia Based on Untargeted Metabolomic Analysis. (2026/05/01) ♡
• [Mechanism of Ding-Zhi-Xiao-Wan on sphingolipid metabolism disorders in Alzheimer's disease based on network pharmacology, molecular docking, and animal experiments]. (2026/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities. (2026/04/29) ♡
• Trends in incidence and mortality of acute and chronic leukaemias in Brazil: challenges and advances over three decades. (2026/04/03) ♡
• Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eμ-TCL1 mice. (2026/04/01) ♡
• Use of dietary and herbal supplements and communication with hematologists regarding such use among patients with CLL: a national survey. (2026/04/01) ♡
• Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort. (2026/03/18) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. (2026/03/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. (2026/03/12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort. (2026/03/10) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Acute Myeloid Leukemia With KMT2A Rearrangement Presenting as Skin Hyperpigmentation. (2026/03/01) ♡
• Discovery of novel imidazo[4,5-b]pyridine derivatives as noncovalent reversible Bruton's tyrosine kinase inhibitors. (2026/03/01) ♡
• T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia. (2026/03/01) ♡
• Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Real-World Evidence on Ibrutinib in First-Line Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma: A Comprehensive Review. (2026/03/01) ♡
• Unveiling the Genetic and Immunophenotypic Landscape of Chronic Lymphocytic Leukemia in Indian Cohort. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies. (2026/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. (2026/03/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (2026/02/20) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. (2026/02/20) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (2026/02/20) ♡
• Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia. (2026/02/19) ♡
• Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. (2026/02/01) ♡
• Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine. (2026/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Bilateral Nongranulomatous Anterior Uveitis with Macular Edema Associated with Ibrutinib Use: A Case Report. (2026/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction. (2026/02/01) ♡
• Chronic lymphocytic leukemia mimicking lung carcinoma: an unusual extranodal and extramedullary presentation of a frequent hematological neoplasm. (2026/01/29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL. (2026/01/27) ♡
• Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia. (2026/01/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. (2026/01/22) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fitness in CLL. (2026/01/21) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence. (2026/01/20) ♡
• Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel. (2026/01/14) ♡
• Prognostic and predictive impact of NOTCH1 mutations in patients with chronic lymphocytic leukemia: a tertiary single-center experience. (2026/01/13) ♡
• A Novel Aberrant HbF Peak with Electrophoretic Shift in A1c of a Patient with Chronic Lymphocytic Leukemia (CLL) Was Reversible to Give Interpretable Results. (2026/01/13) ♡
• Prognostic factors associated with recurrent COVID-19 and impact of SARS-CoV-2 vaccine on patients with chronic lymphocytic leukemia. (2026/01/08) ♡
• REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia. (2026/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. (2026/01/01) ♡
• Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia. (2026/01/01) ♡
• Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. (2026/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients. (2026/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study. (2026/01/01) ♡
• Acetanilide herbicide exposure and lymphoid malignancy risk in the French AGRiculture and CANcer cohort. (2026/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice. (2026/01/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.